FOR PHARMA & Research Partners
We grow with your therapy, not just your trial
From early biomarker strategy to companion diagnostic development and post-approval monitoring, Altum Sequencing supports every phase of your oncology program.
FOR HEALTHCARE PROFESSIONALS
Real-time tumor monitoring that fits your practice
Whether you're tracking residual disease after standard therapy or navigating the complexity of CAR-T and transplant, both assays run on a single sample, giving you the longitudinal data to make confident decisions at every stage of your patient's treatment.
Altum Sequencing works with pharmaceutical companies, hospitals and clinical research organizations across the world.
When imaging is not enough
The 36% Problem
Up to 36% of cancer patients are not correctly diagnosed after treatment.
Which means 8% patients are sent home believing they are health while 28% receive toxic treatments when they don’t actually need.
"Altum Sequencing’s technology provides highly sensitive molecular insights that complement conventional monitoring, helping us better understand disease evolution and improve long-term patient management."
Dr. Joaquín Martínez
Chairman and Co-Founder
Where can this technology help you?
Altum Sequencing's Role in the Cancer Journey
Our integrated technology platform maps directly onto the key decision points of oncology care, from initial diagnosis through therapy selection, treatment monitoring, and long-term surveillance. Click on each product to learn more.
